Melanie Thomas, MD
Hematology & Oncology · Greer, SCNPI 1225134075
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 82.1% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $16,463 and has fallen 99.4% since, to $102 in 2025.
Across 165 payments — averaging $163.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$22K
- Merck$3K
- Johnson & Johnson$346
- Bristol Myers Squibb$285
- Daiichi Sankyo Inc.$142
- AstraZeneca$126
- plus $1K from 32 others
What the payments were for
- Consulting fees$9,93837%
- Speaking & faculty fees$10,50039%
- Travel & lodging$3,60013%
- Food & beverage$2,72110%
- Education$2171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 42 | $22,135 |
| Merck | 12 | $2,672 |
| Johnson & Johnson(2 entities) | 16 | $346 |
| Bristol Myers Squibb | 16 | $285 |
| Daiichi Sankyo Inc. | 7 | $142 |
| AstraZeneca(2 entities) | 8 | $126 |
| AVEO Pharmaceuticals, Inc. | 2 | $118 |
| Novartis | 6 | $106 |
| Tempus AI, Inc | 1 | $87 |
| Sanofi | 5 | $84 |
| GSK | 4 | $73 |
| Genmab U.S., Inc. | 2 | $68 |
| Amgen | 4 | $66 |
| Exelixis Inc. | 4 | $63 |
| Pfizer | 4 | $62 |
| Puma Biotechnology, Inc. | 3 | $45 |
| Beigene USA, Inc. | 2 | $39 |
| Boehringer Ingelheim | 2 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $31 |
| Genentech USA, Inc. | 2 | $30 |
| Pharmacosmos Therapeutics Inc. | 2 | $30 |
| Seagen Inc. | 2 | $29 |
| Morphosys, US Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Menarini Silicon Biosystems, Inc. | 1 | $27 |
| GE HealthCare | 1 | $26 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| AbbVie | 1 | $14 |
| Mirati Therapeutics, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
| Array Biopharma Inc | 1 | $13 |
| Tersera Therapeutics LLC | 1 | $12 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,976 in reported general payments places this provider in the 85th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $16,945 |
| Abiraterone Acetate | 20 | $8,627 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 19 | $643 |
| Anastrozole | 63 | $586 |
| Letrozole | 24 | $438 |
| Prochlorperazine Maleate | 24 | $243 |
| Ibandronate Sodium | 11 | $215 |
| Oxycodone Hcl | 13 | $209 |
| Gabapentin | 18 | $205 |
| Prednisone | 34 | $128 |
| Ondansetron Hcl | 15 | $84 |
| Pregabalin | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $16,94519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greer
- Suzanne FanningGreenville$927K
- Vikas DemblaSpartanburg$568K
- Stephen DyarGreenville$413K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Bhumika PatelGreenville$225K
- Ming LimCharleston$94K
- George GeilsCharleston$76K
- Joe StephensonGreenville$57K
- Sashi NaiduRock Hill$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.